课题基金 / 基金详情

Mediators of Pulmonary Vasodilatation in Liver Disease

Mediators of Pulmonary Vasodilatation in Liver Disease
肝病中肺血管舒张的介质
批准号:
8517099
负责人:
MICHAEL B FALLON
金额:
$29.74万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2014-07-31

项目摘要

项目成果

MICHAEL B FALLON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The hepatopulmonary syndrome (HPS) is an important vascular complication of liver disease where 15-30% of cirrhotic patients develop pulmonary microvascular dilatation causing hypoxemia. The presence of HPS increases mortality and no medical therapies are available. Experimental biliary cirrhosis induced by common bile duct ligation (CBDL) reproduces the pulmonary vascular and gas exchange abnormalities of human HPS. Current cycle shows that hepatic production and release of endothelin-1 (ET-1) and increased pulmonary expression of the endothelin B (ETB) receptor are critical early events that trigger HPS through eNOS derived NO production. Pulmonary ETB receptor expression is also increased in prehepatic portal hypertension but hepatic ET-1 production does not rise and HPS does not develop unless ET-1 is infused. Increased pulmonary ETB receptor levels correlate with the development of a hyperdynamic circulation reflecting increased vascular shear stress, a known modulator of ETB receptor expression. As ET-1 and ETB receptor alterations occur after CBDL, macrophages also accumulate in the pulmonary vasculature and we contributes to the progression of HPS at later time points, by producing heme oxygenase-1 derived carbon monoxide. Whether ET-1 and ETB receptor mediated effects recruit and activate macrophages in the lung is unknown. Preliminary studies support that shear stress and ET-1 contribute to pulmonary ETB receptor overexpression in experimental HPS and reveal that selective ETB receptor inhibition may decrease pulmonary microvascular eNOS, inhibit accumulation of pulmonary intravascular macrophage and improve HPS. Our hypothesis is that shear stress/cytokine induced pulmonary vascular endothelial ETB receptor overexpression mediates ET-1 effects in the endothelium and macrophages in experimental HPS. We will 1) define the cellular mechanisms and consequences of pulmonary vascular endothelial ETB receptor overexpression in cirrhosis and portal hypertension, 2) test if ET-1 and ETB receptor mediated effects contribute to adhesion and activation of monocytes/macrophages in the pulmonary vascular endothelium and 3) assess the role of ETB receptor alterations in the pathogenesis of experimental HPS in vivo.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population.
南德克萨斯州墨西哥裔美国人中丙氨酸氨基转移酶升高的基于人群的危险因素。
DOI: 10.1016/j.arcmed.2012.08.005
发表时间: 2012
期刊: Archives of medical research
影响因子: 7.7
作者: [Qu,Hui-Qi, Li,Quan, Grove,MeganL, Lu,Yang, Pan,Jen-Jung, Rentfro,AnneR, Bickel,PerryE, Fallon,MichaelB, Hanis,CraigL, Boerwinkle,Eric, McCormick,JosephB, Fisher-Hoch,SusanP]
通讯作者: Fisher-Hoch,SusanP
DOI: --
发表时间: 2013
期刊: Transactions of the American Clinical and Climatological Association
影响因子: --
作者: [M. Fallon;Junlan Zhang]
通讯作者: M. Fallon;Junlan Zhang
DOI: 10.1111/jgh.13388
发表时间: 2016-11
期刊: Journal of gastroenterology and hepatology
影响因子: 4.1
作者: [Wu W, Zhang J, Yang W, Hu B, Fallon MB]
通讯作者: Fallon MB
Muscle cramps in liver disease.
肝脏疾病引起的肌肉痉挛。
DOI: 10.1016/j.cgh.2013.03.017
发表时间: 2013
期刊: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子: --
作者: [Mehta,ShivangS, Fallon,MichaelB]
通讯作者: Fallon,MichaelB
11
    Sorafenib for Hepatopulmonary Syndrome
    • 批准号:
      8545389
    • 项目类别:
    • 资助金额:
      $106.29万
    • 财政年份:
      2013
    • 负责人:
      MICHAEL B FALLON
    • 依托单位:
    Sorafenib for Hepatopulmonary Syndrome
    • 批准号:
      8881299
    • 项目类别:
    • 资助金额:
      $203.72万
    • 财政年份:
      2013
    • 负责人:
      MICHAEL B FALLON
    • 依托单位:
    Sorafenib for Hepatopulmonary Syndrome
    • 批准号:
      8724552
    • 项目类别:
    • 资助金额:
      $201.5万
    • 财政年份:
      2013
    • 负责人:
      MICHAEL B FALLON
    • 依托单位:
    HEPATOPULMONARY INVESTIGATIVE GROUP
    海外基金